David Craig’s operating manual for building biotech companies in today’s market is now available in hardcover and as an ...

Analysts have given Alnylam Pharmaceuticals an average price target of $436.

Biotech companies are spending billions to perfect chemical formulas, only to be tripped up by the one variable they forgot ...

They have at least one thing in common: An exciting pipeline.

It has been a banner year for biotech buyouts, and these are two of the prime targets.

Seven life sciences companies cut at least 346 jobs in Massachusetts between April and June, with some of the layoffs tied to ...

Biotech is now the deepest pocket of leadership in the entire Nasdaq. Everyone can see biotech is moving, and the why is ...

Biotech pioneer Genentech will cut 103 jobs in its latest round of layoffs, including its head of cell therapy and 33 ...

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.

By Karen Roman Imviva Biotech said it has FDA authorization for its Investigational Device Exemption application to use ...

Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...